

YOU'VE JOINED THE 3,250+ WHO'VE BEEN PRESCRIBED TAKHZYRO

CLICK TO GET STARTED



The number of patients prescribed TAKHZYRO since 2018 is based on third-party US specialty pharmacy data.

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

**TAKHZYRO**[®]
(lanadelumab-flyo) injection

"I'm going to have HAE for the rest of my life. So knowing TAKHZYRO was studied for as long as it was is really important."

— Kelly
Her TAKHZYRO
experience started
in 2018



Individuals featured are TAKHZYRO patients as of 2023 and are sharing their own experiences. Individual experiences may vary.

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

EFFECTIVE PREVENTION AS SEEN IN A 6.5-MONTH STUDY

You and your doctor likely chose to manage your hereditary angioedema (HAE) with TAKHZYRO for several reasons. One of those may have had to do with the results of the clinical studies. In those studies, people taking TAKHZYRO had fewer HAE attacks on average, and some even had periods of zero attacks.

Some details about the first study

The study lasted 6.5 months and included 125 people with HAE aged 12 years and older.

- The goal was to evaluate the efficacy and safety of TAKHZYRO
- People taking TAKHZYRO 300 mg every 2 weeks saw a **significant reduction in the number of monthly attacks by 87%** on average compared with placebo
- They also had an average of **83% fewer moderate or severe attacks** and **87% fewer attacks requiring on-demand treatment** compared with placebo
- **44%** of people taking TAKHZYRO 300 mg every 2 weeks had **zero attacks during the entire clinical study** compared with 2% taking placebo

TAKHZYRO was also looked at in a long-term, open-label extension study

This study lasted 2.5 years and included 212 people with HAE aged 12 years and older. It looked at the long-term safety and efficacy of TAKHZYRO. Patients knew they were receiving TAKHZYRO, which could have influenced the results. **The study showed similar and consistent results to the first study. For safety results, see page 13.**

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection

SUPPORT FOR YOUR JOURNEY BACKED BY TAKEDA'S 15+ YEARS OF EXPERIENCE

What you can expect when getting your TAKHZYRO

All HAE medications are provided by specialty pharmacies. Insurance companies often require additional information to approve this type of prescription medication. Sometimes it can take a month to coordinate the delivery of your first shipment of TAKHZYRO. **This is normal.**

The good news is, we provide support at no cost to you. And we will work to make sure you get your TAKHZYRO as quickly as possible.

Questions about TAKHZYRO?

You can get answers to FAQs by visiting [TAKHZYRO.com](https://www.takeda.com/takhzyro). Remember to talk to your doctor about any questions you may have.

We've been there for people with HAE since 2008

- TAKHZYRO is the #1 prescribed HAE preventive treatment*
- Takeda has been supporting people with HAE since 2008
- OnePath® has been providing product support services for 12 years
- TAKHZYRO has been evaluated in one of the largest prevention studies in HAE and has been prescribed to over [3,250] people since it was approved in 2018†



“My doctor wanted me to try TAKHZYRO, and I trusted their medical recommendation. TAKHZYRO has definitely made a big difference for me. I'm glad I listened!”

— Dennis

His TAKHZYRO experience started in 2018

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.

†Based on third-party US specialty pharmacy data.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection

START OFF RIGHT WITH TREATMENT GOALS


You and your doctor decided effective prevention with TAKHZYRO could help reduce the frequency and severity of your HAE attacks. As part of your HAE management plan, treatment with TAKHZYRO could also help you achieve your treatment goals.

What do you hope to achieve with TAKHZYRO?

Start by thinking about your experience with HAE today. This will give you a snapshot of your "before TAKHZYRO." After taking TAKHZYRO for a few months, you can see how the frequency and severity of your HAE attacks may have changed. Write down the answers to these questions:

- How often are my attacks now?
- How severe are they?
- How often do I use my on-demand medication?

Watch [Jack's video](#) to hear him talk about setting goals for his HAE management plan.



Setting goals has really helped me track my progress with TAKHZYRO."

— Jack

His TAKHZYRO experience started in 2018

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash


Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection

I continue to take TAKHZYRO as prescribed by my doctor. It's helped decrease my attack frequency and severity."

— Jenny


Her TAKHZYRO experience started in 2018



GIVE TAKHZYRO 2.5 MONTHS TO REACH STEADY STATE

What do we mean by "steady state"?

With your first dose of TAKHZYRO, the medicine will start to build up in your body. **Over the course of your first 6 doses, TAKHZYRO will reach a constant level—also known as "steady state."** Once you get there, it's important to keep taking TAKHZYRO exactly as prescribed to help maintain steady state.



IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection

MAKE A COMMITMENT TO YOURSELF AND TAKHZYRO



Take each dose as prescribed

TAKHZYRO continues to work as you take it, so it is important to take each dose as prescribed by your doctor. **Remember also to avoid missing or skipping doses.**



Breakthrough attacks

It's possible to experience breakthrough attacks while taking TAKHZYRO. Some people may experience them more frequently in the first few months of treatment.

It is recommended to keep your on-demand medication on hand in case of a breakthrough attack.

If a breakthrough attack happens, don't be discouraged. Keep taking TAKHZYRO as prescribed, and talk with your doctor about your experience.



Stay the course

Over time, you may begin to notice your attacks are less severe or that you are using your on-demand treatment less. **These are signs that TAKHZYRO is working.**

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

In a later analysis of the 6.5-month clinical study:



After patients received their sixth dose of TAKHZYRO, **77% had ZERO attacks for the last 4 months of the study.** Compared to 3% of those taking placebo.

- In the same study, **44% of people had zero attacks for the entire 6.5 months** compared with 2% of people taking placebo
- While supportive of the main findings, the results above were not the primary focus of the clinical study. It was not designed to measure the percentage of people who had zero attacks after 2.5 months of treatment through the end of the study

Get dosing reminders!

You can get text message reminders to help you stay on track with TAKHZYRO. [Click here](#) or text SIGNUP (o RECORDAR en español) to 36395.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection

SAFETY RESULTS ESTABLISHED IN ONE OF THE LARGEST PREVENTION STUDIES IN HAE

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have symptoms of an allergic reaction.

The most common side effects seen in both clinical studies included:

- o **Injection site reactions.** These are the most common side effects of TAKHZYRO. People who received TAKHZYRO in the clinical studies reported pain, redness, or bruising in the area where TAKHZYRO was injected. These reactions are expected

- Be sure to follow the administration technique as demonstrated in the Instructions for Use

- Remember, you will be taught how to properly inject TAKHZYRO by a specially trained nurse before your first dose.

Do not attempt to take TAKHZYRO without first being trained by a healthcare provider

- o **Upper respiratory infections.** Common examples are when someone gets a cold or the flu

- o **Headaches**

Just as everyone's experience with HAE is different, every person will respond to medication differently. It is important to share any side effects you may experience with your healthcare provider. They can help you manage them.

You may report side effects to FDA at 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Most common side effects in the 6.5-month clinical study	TAKHZYRO (84 people)*	Placebo (41 people)
Injection site reactions	52%	34%
o Pain	43%	29%
o Redness	10%	2%
o Bruising	7%	0%
Upper respiratory infection	29%	32%
Headache	21%	22%
Rash	7%	5%
Dizziness	6%	0%
Diarrhea	5%	5%
Muscle aches	5%	0%

Safety data from the 2.5-year open-label extension study were consistent with the safety data from the 6.5-month study.

All side effects above occurred in $\geq 10\%$ of people taking TAKHZYRO.

*Includes all people treated with TAKHZYRO (300 mg every 2 weeks, 300 mg every 4 weeks, or 150 mg every 4 weeks) in the first study.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO[®]
(lanadelumab-flyo) injection



GETTING STARTED WITH OnePath®

At OnePath, we provide you with tailored support for your Takeda therapy

When you're prescribed TAKHZYRO® (lanadelumab-flyo), OnePath's dedicated support is here for you.

At OnePath, we see a person, not a patient. We know that living with HAE looks different for everyone. We get to know you, understand who you are, and learn what's most important to you—so we can focus on what you specifically need when it comes to getting your therapy.

You'll be connected with a **Patient Support Manager (PSM)** who acts as your go-to person.

The OnePath team will:

- Address your questions and concerns, and help determine next steps when needed
- Work with your insurance provider to help you receive your treatment
- Enroll you in the OnePath Co-Pay Assistance Program, if you qualify*
- Arrange for a trained nursing professional to teach you how to self-inject TAKHZYRO
- Continue to help support you throughout your TAKHZYRO treatment, even after you have started on therapy

*To be eligible, you must be enrolled in OnePath and have commercial insurance. Other terms and conditions apply. Call OnePath for more details.



OnePath was there for me right when I started TAKHZYRO. And Lisa, my PSM, still calls me to make sure I'm doing OK and getting my treatment on time."

— Soraya
Her TAKHZYRO experience started in 2018

Your PSM will contact you from the main OnePath number **(1-866-888-0660)** to help you get started. Save this number to your phone so you can easily recognize calls from OnePath in the future.

Have questions? Call OnePath at **1-866-888-0660**, Monday through Friday, 8:30 AM to 8:00 PM ET.

If English is not your preferred language, we can communicate with you over the phone using a translation service.

Please see Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

THE #1 PRESCRIBED HAE PREVENTIVE TREATMENT*

- **Clinical results:** In the 6.5-month study, people 12 years of age and older taking TAKHZYRO saw a reduction in the number of monthly attacks by 87% on average compared with placebo
- **Experience:** TAKHZYRO has been prescribed to over 3,250 people since 2018, based on third-party US specialty pharmacy data
- **Support:** OnePath® has been helping to ensure people have access to their treatment and the tools they need for 12 years

[*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.]

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.



©2023 Takeda Pharmaceuticals U.S.A., Inc. 300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. TAKHZYRO is a registered trademark of Dyax Corp., a Takeda company. OnePath is a registered trademark of Shire, a Takeda company. US-LANA-1581v1.0 05/23

Visit us on:



TAKHZYRO[®]
(lanadelumab-flyo) injection